King Wholesaler Agreements Planned To Stabilize Altace Inventory Levels
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the ACE inhibitor will continue to be adversely affected by high inventory levels through the first quarter. Stocking for Skelaxin and Levoxyl appear to have normalized.
You may also be interested in...
Altace Sales Declines Reflect King's Inventory Workdown Program
Wholesaler inventory reductions of the ACE inhibitor totaled $180 mil. in value in 2004, representing almost all of the 35% decline in Altace sales during the year. Wholesale inventory reductions for Altace and Sonata are continuing as King aims for an on-hand supply of 1.5 months.
Altace Sales Declines Reflect King's Inventory Workdown Program
Wholesaler inventory reductions of the ACE inhibitor totaled $180 mil. in value in 2004, representing almost all of the 35% decline in Altace sales during the year. Wholesale inventory reductions for Altace and Sonata are continuing as King aims for an on-hand supply of 1.5 months.
King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product
Amendments to inventory management agreements with wholesalers are aimed at reducing levels to 1.5 months by the end of March. Work-down announcement accompanies King’s restatement of financials; Mylan deal remains up in the air with one week to go before walk-away date.